Feltl analyst highlights Novadaq and TearLab in WSJ interview
The Wall Street Journal has announced its 2012 “Best On The Street” stock picker rankings, with Feltl analyst, Ben Haynor, coming second in the Medical Equipment & Supplies category.
In an interview with the WSJ, Mr. Haynor called Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) his “best call” during 2012 and said TearLab (NASDAQ:TEAR; TSX:TLB) is the “most intriguing stock in my space at the moment.”
Mr. Haynor initiated coverage of Novadaq in 2012 when it was a “relatively undiscovered story,” with only a handful of analysts following the company. The stock more than doubled following his initiation report and finished out 2012 up 59.4% from his initial coverage.
He said TearLab is still relatively undiscovered by investors and is early in its roll-out of a first-of-its-kind, point-of-care diagnostic platform to diagnose dry eye disease, which impacts some 30 million Americans. “In my view, they have the Holy Grail in market positioning, with regulatory approvals already secured, reimbursement largely in place, a massive potential market, and essentially no competition.
A copy of the article can be accessed here.